Page 12 - ஆய்வகங்கள் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck Pharma gives voluntary licences to five Indian companies on molnupiravir April 27, 2021 Molnupiravir is being studied in a Phase 3 trial for treatment of non-hospitalised Covid patients MSD Pharmaceuticals has announced non-exclusive voluntary licensing agreements on its investigational oral drug molnupiravir, with five Indian generic manufacturers. The licensees are Cipla, Dr Reddy’s Laboratories Limited, Emcure Pharmaceuticals, Hetero Labs and Sun Pharma, who have World Health Organization pre-qualified manufacturing facilities and experience as major suppliers to global and key low and middle income procurers, Merck Pharma said. Under the agreements, Merck & Co Inc will provide licences to these manufacturers to supply molnupiravir to India and more than 100 LMICs (low- and middle-income countries). Merck & Co is also in discussions with the Medicines Patent Pool to explore the potential for additional licences, it added.

Sun pharmaMerck pharmaRehana khanRidgeback biotherapeuticsKennethc frazierMerck co incDr reddy laboratoriesWorld health organizationEmcure pharmaceuticalsMerck coMsd pharmaceuticalsLaboratories limitedHetero labsMedicines patent poolMerck sharpManaging director